Zeev Meiner1, Emmeline Ayers2, David A Bennett3, Cuiling Wang4, Joe Verghese2,5. 1. Department of Physical Medicine and Rehabilitation, Hadassah Mount Scopus, Jerusalem, Israel. 2. Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA. 3. Department of Neurology, Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA. 4. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA. 5. Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
Abstract
BACKGROUND AND PURPOSE: Motoric cognitive risk syndrome (MCR) is a predementia syndrome characterized by cognitive complaints and slow gait. MCR is associated with increased risk of cognitive decline and incident dementia. Predictors of transition to dementia in MCR patients are still obscure. METHODS: We examined clinical, biological and lifestyle parameters related to conversion to dementia using Cox models in 439 older adults with prevalent MCR (mean age 79.87 ± 8.13 years, 70% women) from two cohorts, 268 from the Chicago-based Rush Memory and Aging project (MAP) and 171 from the Religious Orders Study (ROS), which enrolled religious clergy across the United States. RESULTS: In the pooled sample, 439 (13.2%) had prevalent MCR (268 MAP and 171 ROS). There were 140 (31.9%) incident dementia cases over a median follow up of 4.0 years. Age predicted conversion from MCR to dementia in both cohorts. Male gender was a risk factor only in ROS. In the pooled data, only higher depressive symptoms were associated with higher risk of conversion to dementia (adjusted hazard ratio [aHR] 1.13, 95% CI 1.03-1.24). Lower cognitive activity participation (aHR 0.59, 95% CI 0.44-0.79) and apolipoprotein E ε4 allele (aHR 2.57, 95% CI 1.48-4.45) predicted conversion to dementia in MAP. CONCLUSIONS: Depressive symptoms and other cohort-specific risk factors were identified as predictors of transition to dementia in individuals with MCR. These findings suggest common pathological mechanisms underlying mood, gait and cognitive declines in aging, which could help develop preventive strategies.
BACKGROUND AND PURPOSE: Motoric cognitive risk syndrome (MCR) is a predementia syndrome characterized by cognitive complaints and slow gait. MCR is associated with increased risk of cognitive decline and incident dementia. Predictors of transition to dementia in MCR patients are still obscure. METHODS: We examined clinical, biological and lifestyle parameters related to conversion to dementia using Cox models in 439 older adults with prevalent MCR (mean age 79.87 ± 8.13 years, 70% women) from two cohorts, 268 from the Chicago-based Rush Memory and Aging project (MAP) and 171 from the Religious Orders Study (ROS), which enrolled religious clergy across the United States. RESULTS: In the pooled sample, 439 (13.2%) had prevalent MCR (268 MAP and 171 ROS). There were 140 (31.9%) incident dementia cases over a median follow up of 4.0 years. Age predicted conversion from MCR to dementia in both cohorts. Male gender was a risk factor only in ROS. In the pooled data, only higher depressive symptoms were associated with higher risk of conversion to dementia (adjusted hazard ratio [aHR] 1.13, 95% CI 1.03-1.24). Lower cognitive activity participation (aHR 0.59, 95% CI 0.44-0.79) and apolipoprotein E ε4 allele (aHR 2.57, 95% CI 1.48-4.45) predicted conversion to dementia in MAP. CONCLUSIONS: Depressive symptoms and other cohort-specific risk factors were identified as predictors of transition to dementia in individuals with MCR. These findings suggest common pathological mechanisms underlying mood, gait and cognitive declines in aging, which could help develop preventive strategies.
Authors: Harmehr Sekhon; Gilles Allali; Cyrille P Launay; John Barden; Tony Szturm; Teresa Liu-Ambrose; Victoria L Chester; Chek Hooi Wong; Olivier Beauchet Journal: Maturitas Date: 2019-02-18 Impact factor: 4.342
Authors: Paul K Crane; Laura E Gibbons; Kristen Dams-O'Connor; Emily Trittschuh; James B Leverenz; C Dirk Keene; Joshua Sonnen; Thomas J Montine; David A Bennett; Sue Leurgans; Julie A Schneider; Eric B Larson Journal: JAMA Neurol Date: 2016-09-01 Impact factor: 18.302
Authors: Raj C Shah; Robert S Wilson; Julia L Bienias; Zoe Arvanitakis; Denis A Evans; David A Bennett Journal: Neuroepidemiology Date: 2005-10-25 Impact factor: 3.282
Authors: Zoe Arvanitakis; Sue E Leurgans; Debra A Fleischman; Julie A Schneider; Kumar B Rajan; Jeremy J Pruzin; Raj C Shah; Denis A Evans; Lisa L Barnes; David A Bennett Journal: Ann Neurol Date: 2018-03-30 Impact factor: 10.422
Authors: Ronald C Petersen; Oscar Lopez; Melissa J Armstrong; Thomas S D Getchius; Mary Ganguli; David Gloss; Gary S Gronseth; Daniel Marson; Tamara Pringsheim; Gregory S Day; Mark Sager; James Stevens; Alexander Rae-Grant Journal: Neurology Date: 2017-12-27 Impact factor: 9.910
Authors: Grace J Lee; Po H Lu; Xue Hua; Suh Lee; Stephanie Wu; Ken Nguyen; Edmond Teng; Alex D Leow; Clifford R Jack; Arthur W Toga; Michael W Weiner; George Bartzokis; Paul M Thompson Journal: Biol Psychiatry Date: 2012-02-08 Impact factor: 13.382
Authors: David A Bennett; Robert S Wilson; Julie A Schneider; Julia L Bienias; Steven E Arnold Journal: Am J Geriatr Psychiatry Date: 2004 Mar-Apr Impact factor: 4.105